Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470741 · ClinicalTrials.gov registry record · Phase 4
Pilot of Letrozole for Uterine Myomas
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT02470741 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 12 participants.
The verdict
NCT02470741, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).
Interventions
- OTHER Placebo
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02470741
The ClinicalTrials.gov registry entry for NCT02470741 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02470741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02470741 about?
NCT02470741 is a clinical study titled "Pilot of Letrozole for Uterine Myomas". PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day...
What is the current status of trial NCT02470741?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2015-07. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02470741?
The interventions under investigation include: Placebo (OTHER), Letrozole (DRUG).
Who is sponsoring clinical trial NCT02470741?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.